Batya Isaacson

3.2k total citations · 1 hit paper
22 papers, 1.1k citations indexed

About

Batya Isaacson is a scholar working on Immunology, Epidemiology and Oncology. According to data from OpenAlex, Batya Isaacson has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 11 papers in Epidemiology and 6 papers in Oncology. Recurrent topics in Batya Isaacson's work include Immune Cell Function and Interaction (12 papers), CAR-T cell therapy research (6 papers) and Fungal Infections and Studies (4 papers). Batya Isaacson is often cited by papers focused on Immune Cell Function and Interaction (12 papers), CAR-T cell therapy research (6 papers) and Fungal Infections and Studies (4 papers). Batya Isaacson collaborates with scholars based in Israel, United States and Germany. Batya Isaacson's co-authors include Ofer Mandelboim, Gilad Bachrach, Zvi Granot, Amjad Shhadeh, Ariella Glasner, Aviram Nissan, Jawad Abed, Judith Sandbank, Einav Yehuda‐Shnaidman and Falk Ponath and has published in prestigious journals such as Nature Communications, Immunity and Journal of Virology.

In The Last Decade

Batya Isaacson

22 papers receiving 1.1k citations

Hit Papers

Breast cancer colonization by Fusobacterium nucleatum acc... 2020 2026 2022 2024 2020 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Batya Isaacson Israel 11 402 375 373 133 106 22 1.1k
Leonie Brockmann Germany 10 709 1.8× 275 0.7× 224 0.6× 79 0.6× 83 0.8× 12 1.1k
Almohanad A. Alkayyal Saudi Arabia 12 321 0.8× 374 1.0× 273 0.7× 73 0.5× 59 0.6× 29 903
Raphaël Carapito France 20 386 1.0× 200 0.5× 363 1.0× 48 0.4× 144 1.4× 67 1.2k
Ahmad Bakur Mahmoud Saudi Arabia 18 547 1.4× 303 0.8× 323 0.9× 44 0.3× 120 1.1× 42 1.1k
Michela Spadaro Italy 18 599 1.5× 322 0.9× 334 0.9× 85 0.6× 53 0.5× 39 1.1k
Federica Pericle United States 27 1.2k 3.0× 595 1.6× 557 1.5× 158 1.2× 94 0.9× 42 1.9k
Ekaterina Nikitina Russia 12 996 2.5× 574 1.5× 358 1.0× 32 0.2× 83 0.8× 19 1.5k
Michael R. Olin United States 25 519 1.3× 294 0.8× 313 0.8× 59 0.4× 188 1.8× 46 1.6k
Olivier Moralès France 21 634 1.6× 293 0.8× 369 1.0× 24 0.2× 118 1.1× 59 1.3k
Zachary Roberts United States 16 412 1.0× 362 1.0× 279 0.7× 43 0.3× 56 0.5× 34 1.1k

Countries citing papers authored by Batya Isaacson

Since Specialization
Citations

This map shows the geographic impact of Batya Isaacson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Batya Isaacson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Batya Isaacson more than expected).

Fields of papers citing papers by Batya Isaacson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Batya Isaacson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Batya Isaacson. The network helps show where Batya Isaacson may publish in the future.

Co-authorship network of co-authors of Batya Isaacson

This figure shows the co-authorship network connecting the top 25 collaborators of Batya Isaacson. A scholar is included among the top collaborators of Batya Isaacson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Batya Isaacson. Batya Isaacson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Charpak‐Amikam, Yoav, Batya Isaacson, Ronen Ben‐Ami, et al.. (2024). The activating receptor NKG2D is an anti-fungal pattern recognition receptor. Nature Communications. 15(1). 8664–8664. 2 indexed citations
2.
Kahlon, Shira, Batya Isaacson, Moriya Gamliel, et al.. (2024). Pregnancy trained decidual NK cells protect pregnancies from harmful Fusobacterium nucleatum infection. PLoS Pathogens. 20(1). e1011923–e1011923. 4 indexed citations
3.
Stein, Natan, et al.. (2023). Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST. iScience. 26(8). 107284–107284. 1 indexed citations
5.
Charpak‐Amikam, Yoav, Batya Isaacson, Tal Levinson, et al.. (2022). Candida albicans evades NK cell elimination via binding of Agglutinin-Like Sequence proteins to the checkpoint receptor TIGIT. Nature Communications. 13(1). 2463–2463. 18 indexed citations
6.
Shhadeh, Amjad, Ariana Umaña, Christopher C. Yoo, et al.. (2021). Fusobacterium nucleatum CbpF Mediates Inhibition of T Cell Function Through CEACAM1 Activation. Frontiers in Cellular and Infection Microbiology. 11. 692544–692544. 45 indexed citations
7.
Isaacson, Batya, Rachel Yamin, Gilad Bachrach, et al.. (2021). The inhibitory receptor CD300a is essential for neutrophil‐mediated clearance of urinary tract infection in mice. European Journal of Immunology. 51(9). 2218–2224. 6 indexed citations
8.
Sol, Asaf, Deborah Nejman, Amjad Shhadeh, et al.. (2020). Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nature Communications. 11(1). 3259–3259. 471 indexed citations breakdown →
9.
Isaacson, Batya, Orit Berhani, Yoav Charpak‐Amikam, et al.. (2020). Altered NKp46 Recognition and Elimination of Influenza B Viruses. Viruses. 13(1). 34–34. 7 indexed citations
10.
Reches, Adi, Natan Stein, Batya Isaacson, et al.. (2020). Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for ImmunoTherapy of Cancer. 8(1). e000266–e000266. 90 indexed citations
11.
Isaacson, Batya & Ofer Mandelboim. (2019). Natural killer cells control metastasis via structural editing of primary tumors in mice. Cancer Immunology Immunotherapy. 68(10). 1721–1724. 4 indexed citations
12.
Glasner, Ariella, Assi Levi, Jonatan Enk, et al.. (2018). NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 48(1). 107–119.e4. 173 indexed citations
13.
Isaacson, Batya, et al.. (2018). Quantification of Bacterial Attachment to Tissue Sections. BIO-PROTOCOL. 8(5). 2 indexed citations
14.
Glasner, Ariella, Batya Isaacson, Sergey Viukov, et al.. (2017). Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression. Scientific Reports. 7(1). 13090–13090. 16 indexed citations
15.
Glasner, Ariella, Batya Isaacson, & Ofer Mandelboim. (2017). Expression and function of NKp46 W32R: the human homologous protein of mouse NKp46 W32R (Noé). Scientific Reports. 7(1). 40944–40944. 6 indexed citations
16.
Bar‐On, Yotam, Yoav Charpak‐Amikam, Ariella Glasner, et al.. (2017). NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy. Journal of Virology. 91(19). 16 indexed citations
17.
Isaacson, Batya, Ariella Glasner, Chamutal Gur, et al.. (2017). Stromal Cell-Derived Factor 1 Mediates Immune Cell Attraction upon Urinary Tract Infection. Cell Reports. 20(1). 40–47. 28 indexed citations
18.
19.
Vitenshtein, Alon, Yoav Charpak‐Amikam, Rachel Yamin, et al.. (2016). NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7. Cell Host & Microbe. 20(4). 527–534. 70 indexed citations
20.
Glasner, Ariella, Ziv Roth, Alexander Varvak, et al.. (2015). Identification of putative novel O-glycosylations in the NK killer receptor Ncr1 essential for its activity. Cell Discovery. 1(1). 15036–15036. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026